Abstract
Rationale
Beneficial effects of aripiprazole on cognition in schizophrenia have been previously reported, but not in recent onset schizophrenia. Cognitive impairments have also been associated with catechol-O-methyltransferase (COMT), methylenetetrahydrofolate reductase (MTHFR), and serotonin transporter (SERT) gene polymorphisms which were earlier implicated in the pathophysiology of schizophrenia.
Objectives
This study examined the short-term influence of aripiprazole long-acting injectable (LAI) as well as of COMT, MTHFR, and SERT gene polymorphisms and their interactions on clinical features and cognitive functions in inpatients with recent onset schizophrenia.
Methods
This study included 98 inpatients suffering from recent onset schizophrenia diagnosed according to DSM-5 criteria. Three months after initiating aripiprazole LAI, the severity of symptoms was assessed by the Positive and Negative Syndrome Scale (PANSS), while cognitive functions were measured by 5-KOG test for cognition. Genotypes of SERT, MTHFR, and COMT gene were determined by different polymerase chain reaction (PCR) methods.
Results
Three-month aripiprazole LAI treatment was associated with a statistically significant change of PANSS total (p<0.001) and subscale scores as well as cognitive parameters of delayed recall (p<0.03), attention (p<0.01), and executive functions in the form of less perseverations (p<0.03), without influencing other examined cognitive functions. However, it significantly influenced composite cognitive score (p<0.02). In regard to the investigated genetic polymorphisms, we established a positive association between the COMT polymorphism (M/M allele carriers) and attention (p<0.01). Additionally, we also established a positive association between the COMT – MTHFR interaction and attention (p<0.02), as well as perseveration item belonging to executive functions (p<0.01). Two other investigated polymorphisms (MTHFR and SERT) were not significantly associated with cognitive indices. Investigated genetic polymorphisms and their interactions were not associated with PANSS scores.
Conclusions
Our findings suggest that aripiprazole LAI improves individual cognitive functions in recent onset schizophrenia. Investigated COMT polymorphism (Met/Met genotype), as well as the COMT-MTHFR interaction, were positively associated with attention and executive functioning (perseveration), potentially implying COMT’s biomarker potential in terms of cognition in schizophrenia.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
References
Almeida OP, Flicker L, Lautenschlager NT, Leedman P, Vasikaran S, van Bockxmeer FM (2005) Contribution of the MTHFR gene to the causal pathway for depression, anxiety and cognitive impairment in later life. Neurobiol Aging 26(2):251–257. https://doi.org/10.1016/j.neurobiolaging.2004.03.007
Barnett JH, Jones PB, Robbins TW, Müller U (2007) Effects of the catechol-O-methyltransferase Val158Met polymorphism on executive function: a meta-analysis of the Wisconsin Card Sort Test in schizophrenia and healthy controls. Mol Psychiatry 12(5):502–509. https://doi.org/10.1038/sj.mp.4001973
Bervoets C, Morrens M, Vansteelandt K, Kok F, de Patoul A, Halkin V, Pitsi D, Constant E, Peuskens J, Sabbe B (2012) Effect of aripiprazole on verbal memory and fluency in schizophrenic patients : results from the ESCAPE study. CNS Drugs 26(11):975–982. https://doi.org/10.1007/s40263-012-0003-4
Biagi E, Capuzzi E, Colmegna F, Mascarini A, Brambilla G, Ornaghi A, Santambrogio J, Clerici M (2017) Long-acting injectable antipsychotics in schizophrenia: literature review and practical perspective, with a focus on aripiprazole once-monthly. Adv Ther 34(5):1036–1048. https://doi.org/10.1007/s12325-017-0507-x
Bilder RM, Reiter G, Bates J, Lencz T, Szeszko P, Goldman RS, Robinson D, Lieberman JA, Kane JM (2006) Cognitive development in schizophrenia: follow-back from the first episode. J Clin Exp Neuropsychol 28(2):270–282. https://doi.org/10.1080/13803390500360554
Bora E, Murray RM (2014) Meta-analysis of cognitive deficits in ultra-high risk to psychosis and first-episode psychosis: do the cognitive deficits progress over, or after, the onset of psychosis? Schizophr Bull 40(4):744–755. https://doi.org/10.1093/schbul/sbt085
Božina N, Mihaljević-Peleš A, Sagud M, Jakovljević M, Sertić J (2006) Serotonin transporter polymorphism in Croatian patients with major depressive disorder. Psychiatr Danub 18(1-2):83–89
Contreras J, Hare L, Camarena B, Glahn D, Dassori A, Medina R, Contreras S, Ramirez M, Armas R, Munoz R, Mendoza R, Raventos H, Ontiveros A, Nicolini H, Palmer R, Escamilla M (2009) The serotonin transporter 5-HTTPR polymorphism is associated with current and lifetime depression in persons with chronic psychotic disorders. Acta Psychiatr Scand 119(2):117–127. https://doi.org/10.1111/j.1600-0447.2008.01273.x
Di Lorenzo R, Ferri P, Cameli M, Rovesti S, Piemonte C (2019) Effectiveness of 1-year treatment with long-acting formulation of aripiprazole, haloperidol, or paliperidone in patients with schizophrenia: retrospective study in a real-world clinical setting. Neuropsychiatr Dis Treat 15:183–198. https://doi.org/10.2147/NDT.S189245
Durga J, van Boxtel MP, Schouten EG, Bots ML, Kok FJ, Verhoef P (2006) Folate and the methylenetetrahydrofolate reductase 677C→T mutation correlate with cognitive performance. Neurobiol Aging 27(2):334–343. https://doi.org/10.1016/j.neurobiolaging.2005.01.003
Egan MF, Goldberg TE, Kolachana BS, Callicott JH (2001) Effect of COMT Val108/158 Met genotype on frontal lobe function and risk for schizophrenia. Proc Natl Acad Sci U S A 98(12):6917–6922. https://doi.org/10.1073/pnas.111134598
First MB, Williams JBW, Karg RS (2015) Structured clinical interview for DSM-5 research version (SCID-5 for DSM-5, Research Version; SCID-5-RV). American Psychiatric Publishing, Arlington.
Frosst P, Blom HJ, Milos R, Goyette P, Sheppard CA, Matthews RG, Boers GJH, den Heijer M, Kluijtmans LAJ, van den Heuve LP, Rozen R (1995) A candidate genetic risk factor for vascular disease: a common mutation in methylenetetrahydrofolate reductase. Nat Genet 10(1):111–113. https://doi.org/10.1038/ng0595-111
Giordano G, Tomassini L, Cuomo I, Amici E, Perrini F, Callovini G, Carannante A, Kotzalidis GD, De Filippis S (2020) Aripiprazole long-acting injection during first episode schizophrenia-an exploratory analysis. Front Psychiatry 10:935. https://doi.org/10.3389/fpsyt.2019.00935
Guo X, Zhai J, Wei Q, Twamley EW, Jin H, Fang M, Hu M, Zhao J (2011) Neurocognitive effects of first and second-generation antipsychotic drugs in early-stage schizophrenia: a naturalistic 12-month follow-up study. Neurosci Lett 503(2):141–146. https://doi.org/10.1016/j.neulet.2011.08.027
Han DH, Park DB, Choi TY, Joo SY, Lee MK, Park BRG, Nishimura R, Chu CC, Renshaw PF (2008) Effects of brain-derived neurotrophic factor-catecholamine-O-methyltransferase gene interaction on schizophrenic symptoms. Neuroreport 19(11):1155–1158. https://doi.org/10.1097/WNR.0b013e32830867ad
Hori H, Yoshimura R, Katsuki A, Hayashi K, Ikenouchi-Sugita A, Umene-Nakano W, Jun N (2012) The cognitive profile of aripiprazole differs from that of other atypical antipsychotics in schizophrenia patients. J Psychiatr Res 46(6):757–761. https://doi.org/10.1016/j.jpsychires.2012.02.013
Kaneko H, Miura I, Kanno-Nozaki K, Horikoshi S, Hino M, Yabe H (2018) COMT Val 108/158 Met polymorphism and treatment response to aripiprazole in patients with acute schizophrenia. Neuropsychiatr Dis Treat 14:1657–1663. https://doi.org/10.2147/NDT.S164647
Kay SR, Fiszbein A, Opfer LA (1987) The Positive and Negative Syndrome Scale (PANSS) for schizophrenia. Schizophr Bull 13(2):261–276. https://doi.org/10.1093/schbul/13.2.261
Kern RS, Green MF, Cornblatt BA, Owen JR, McQuade RD, Carson WH, Ali M, Marcus R (2006) The neurocognitive effects of aripiprazole: an open-label comparison with olanzapine. Psychopharmacology 187(3):312–320. https://doi.org/10.1007/s00213-006-0428-x
Khanna P, Suo T, Komossa K, Ma H, Rummel-Kluge C, El-Sayeh HG, Leucht S, Xia J (2014) Aripiprazole versus other atypical antipsychotics for schizophrenia. Cochrane Database Syst Rev 2:CD006569. https://doi.org/10.1002/14651858.CD006569.pub5
Kontis D, Theochari E, Fryssira H, Kleisas S, Sofocleous C, Andreopoulou A, Kalogerakou S, Gazi A, Boniatsi L, Chaidemenos A, Tsaltas E (2013) COMT and MTHFR polymorphisms interaction on cognition in schizophrenia: an exploratory study. Neurosci Lett 537:17–22. https://doi.org/10.1016/j.neulet.2013.01.012
Konneker TI, Crowley JJ, Quackenbush CR, Keefe RSE, Perkins DO, Scott Stroup T, Lieberman JA, van den Oord E, Sullivan PF (2010) No association of the serotonin transporter polymorphisms 5HTTLPR and rs25531 with schizophrenia or neurocognition. Am J Med Genet B Neuropsychiatr Genet 153B(5):1115–1117. https://doi.org/10.1002/ajmg.b.31077
Križanac I, Matešić K, Karlović D (2020) 5 - KOG Test performance on patients with schizophrenia, alcoholism and depression. Archives of Psychiatry Research 56(2):143–154. https://doi.org/10.20471/dec.2020.56.02.03
Lachman HM, Papolos DF, Saito T, Yu YM, Szumlanski CL, Weinshilboum RM (1996) Human catechol-O-methyltransferase pharmacogenetics: description of a functional polymorphism and its potential application to neuropsychiatric disorders. Pharmacogenetics 6(3):243–250. https://doi.org/10.1097/00008571-199606000-00007
Lee JG, Lee JH, Ha EK, Kim MC, Kim YH (2006) Switching patients with chronic schizophrenia to aripiprazole: the improvement in cognitive function. Clin Psychopharmacol Neurosci 4(1):32–39
Lee BJ, Lee SJ, Kim MK, Lee JG, Park SW, Kim GM, Kim YH (2013) Effect of aripiprazole on cognitive function and hyperprolactinemia in patients with schizophrenia treated with risperidone. Clin Psychopharmacol Neurosci 11(2):60–66. https://doi.org/10.9758/cpn.2013.11.2.60
Lindenmayer JP, Khan A, Lachman H, McGurk SR, Goldring A, Thanju A, Kaushik S (2015) COMT genotype and response to cognitive remediation in schizophrenia. Schizophr Res 168(1-2):279–284. https://doi.org/10.1016/j.schres.2015.07.037
Maat A, Cahn W, Gijsman HJ, Hovens JE, Kahl RS, Aleman A (2014) Open, randomized trial of the effects of aripiprazole versus risperidone on social cognition in schizophrenia. Eur Neuropsychopharmacol 24(4):575–584. https://doi.org/10.1016/j.euroneuro.2013.12.009
Madsen K, Erritzoe D, Mortensen EL, Gade A, Madsen J, Baaré W, Knudsen GM, Hasselbalch SG (2011) Cognitive function is related to fronto-striatal serotonin transporter levels--a brain PET study in young healthy subjects. Psychopharmacology 213(2-3):573–581. https://doi.org/10.1007/s00213-010-1926-4
Mallet J, Gorwood P, Le Strat Y, Dubertret C (2019) Major depressive disorder (MDD) and schizophrenia- addressing unmet needs with partial agonists at the D2 receptor: a review. Int J Neuropsychopharmacol 22(10):651–664. https://doi.org/10.1093/ijnp/pyz043
Mata I, Perez-Iglesias R, Pelayo-Teran JM, Rodríguez-Sanchez JM, Gonzalez-Blanch C, Carrasco-Marin E, Vazquez-Barquero JL, Crespo-Facorro B (2008) Lack of influence of COMT Val158Met genotype on cognition in first-episode non-affective psychosis. Schizophr Res 102(1-3):206–209. https://doi.org/10.1016/j.schres.2008.02.011
Matsuda Y, Sato S, Iwata K, Furukawa S, Hatsuse N, Watanabe Y, Anzai N, Kishimoto T, Ikebuchi E (2014) Effects of risperidone and aripiprazole on neurocognitive rehabilitation for schizophrenia. Psychiatry Clin Neurosci 68(6):425–431. https://doi.org/10.1111/pcn.12147
Mesholam-Gately RI, Giuliano AJ, Goff KP, Faraone SV, Seidman LJ (2009) Neurocognition in first-episode schizophrenia: a meta-analytic review. Neuropsychology 23(3):315–336. https://doi.org/10.1037/a0014708
Mucci A, Piegari G, Galderisi S (2008) Cognitive-enhancing effects of aripiprazole: a case report. Clin Pract Epidemiol Ment Health 4:24. https://doi.org/10.1186/1745-0179-4-24
Nkam I, Ramoz N, Breton F, Mallet J, Gorwood P, Dubertret C (2017) Impact of DRD2/ANKK1 and COMT polymorphisms on attention and cognitive functions in schizophrenia. PLoS One 12(1):e0170147. https://doi.org/10.1371/journal.pone.0170147
Pantelis C, Wood SJ, Proffitt TM, Testa R, Mahony K, Brewer WJ, Buchanan J-A, Velakoulis D, McGorry PD (2009) Attentional set-shifting ability in first-episode and established schizophrenia: relationship to working memory. Schizophr Res 112(1-3):104–113. https://doi.org/10.1016/j.schres.2009.03.039
Peitl V, Štefanović M, Karlović D (2017) Depressive symptoms in schizophrenia and dopamine and serotonin gene polymorphisms. Prog Neuro-Psychopharmacol Biol Psychiatry 77:209–215. https://doi.org/10.1016/j.pnpbp.2017.04.011
Riedel M, Spellmann I, Schennach-Wolff R, Musil R, Dehning S, Cerovecki A, Opgen-Rhein M, Matz J, Seemüller F, Obermeier M, Severus E, Engel RR, Müller N, Möller H-J (2010) Effect of aripiprazole on cognition in the treatment of patients with schizophrenia. Pharmacopsychiatry 43(2):50–57. https://doi.org/10.1055/s-0029-1239539
Robinson DG, Gallego JA, John M, Petrides G, Hassoun Y, Zhang J-P, Lopez L, Braga RJ, Sevy SM, Addington J, Kellner CH, Tohen M, Naraine M, Bennett N, Greenberg J, Lencz T, Correll CU, Kane JM, Malhotra AK (2015) A randomized comparison of aripiprazole and risperidone for the acute treatment of first-episode schizophrenia and related disorders: 3-month outcomes. Schizophr Bull 41(6):1227–1236. https://doi.org/10.1093/schbul/sbv125
Roffman JL, Weiss AP, Deckersbach T, Freudenreich O, Henderson DC, Wong DH, Halsted CH, Goff DC (2008) Interactive effects of COMT Val108/158Met and MTHFR C677 T on executive function in schizophrenia. Am J Med Genet B Neuropsychiatr Genet 147B(6):990–995. https://doi.org/10.1002/ajmg.b.30684
Schreiber R, Newman-Tancredi A (2014) Improving cognition in schizophrenia with antipsychotics that elicit neurogenesis through 5-HT(1A) receptor activation. Neurobiol Learn Mem 110:72–80. https://doi.org/10.1016/j.nlm.2013.12.015
Seo D, Patrick CJ, Kennealy PJ (2008) Role of serotonin and dopamine system interactions in the neurobiology of impulsive aggression and its comorbidity with other clinical disorders. Aggress Violent Behav 13(5):383–395. https://doi.org/10.1016/j.avb.2008.06.003
Sheffield JM, Karcher NR, Barch DM (2018) Cognitive deficits in psychotic disorders: a lifespan perspective. Neuropsychol Rev 28(4):509–533. https://doi.org/10.1007/s11065-018-9388-2
Sheehan DV, Lecrubier Y, Harnett Sheehan K, Janavs J, Weiller E, Bonara LI, Keskiner A, Schinka J, Knapp E, Sheehan MF, Dunbar GC (1997) The validity of the Mini International Neuropsychiatric Interview (MINI) according to the SCID-P and its reliability. Eur Psychiatry 12(5):232–241. https://doi.org/10.1016/S0924-9338(97)83297-X
Steen NE, Aas M, Simonsen C, Dieset I, Tesli M, Nerhus M, Gardsjord E, Mørch R, Agartz I, Melle I, Ueland T, Spigset O, Andreassen OA (2017) Serum levels of second-generation antipsychotics are associated with cognitive function in psychotic disorders. World J Biol Psychiatry 18(6):471–482. https://doi.org/10.1080/15622975.2016.1245441
Strous RD, Lapidus R, Viglin D, Kotler M, Lachman HM (2006) Analysis of an association between the COMT polymorphism and clinical symptomatology in schizophrenia. Neurosci Lett 393(2-3):170–173. https://doi.org/10.1016/j.neulet.2005.09.067
Trampush JW, Lencz T, DeRosse P, John M, Gallego JA, Petrides G, Hassoun Y, Zhang J-P, Addington J, Kellner CH, Tohen M, Burdick KE, Goldberg TE, Kane JM, Robinson DG, Malhotra AK (2015) Relationship of cognition to clinical response in first-episode schizophrenia spectrum disorders. Schizophr Bull 41(6):1237–1247. https://doi.org/10.1093/schbul/sbv120
Wang J, Hu M, Guo X, Wu R, Li L, Zhao J (2013) Cognitive effects of atypical antipsychotic drugs in first-episode drug-naïve schizophrenic patients. Neural Regen Res 8(3):277–286. https://doi.org/10.3969/j.issn.1673-5374.2013.03.011
Woodward ND, Purdon SE, Meltzer HY, Zald DH (2005) A meta-analysis of neuropsychological change to clozapine, olanzapine, quetiapine, and risperidone in schizophrenia. Int J Neuropsychopharmacol 8(3):457–472. https://doi.org/10.1017/S146114570500516X
Woodward ND, Jayathilake K, Meltzer HY (2007) COMT val108/158met genotype, cognitive function, and cognitive improvement with clozapine in schizophrenia. Schizophr Res 90(1-3):86–96. https://doi.org/10.1016/j.schres.2006.10.002
Acknowledgements
The authors would like to thank to all of the healthcare staff and patients who participated in this study.
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Conflict of interest
The authors declare that no competing interests.
Additional information
Publisher’s note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
Rights and permissions
About this article
Cite this article
Peitl, V., Štefanović, M., Orlović, I. et al. Long acting aripiprazole influences cognitive functions in recent onset schizophrenia. Psychopharmacology 238, 1563–1573 (2021). https://doi.org/10.1007/s00213-021-05788-w
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s00213-021-05788-w